Elucidata

Elucidata, founded in 2015, is a pioneering company at the intersection of AI, Machine Learning, and Life Sciences. Headquartered in the United States, Elucidata is transforming the biotech landscape with its innovative data harmonization platform, Polly. Polly is crucial for research and development, allowing scientists to focus on cutting-edge discoveries rather than data management, ultimately accelerating the development of over 40+ FDA-Track Drugs.

Recognized as the 'Most Innovative Biotech Company, 2024' by Fast Company, Elucidata offers a solution to the extensive data wrangling prevalent in early R&D, Precision Diagnostics, and Translational Biomarker research. Polly converts multi-modal biomedical data, such as Omics and Real World Data, into a Unified Data Model, facilitating applications like patient stratification and biomarker discovery. Its client roster includes prestigious names like Pfizer and Janssen Pharmaceuticals.

The company secured a $16M Series A funding in September 2022 from prominent investors including Eight Roads Ventures and F-Prime Capital. With a robust team of 120+ experts across the US and India, Elucidata is well-positioned to continue leading advancements in biotech innovation.